GH-axis peptides: weighing the evidence

The three peptides people ask about most for growth-hormone-axis support, tesamorelin, CJC-1295 and ipamorelin, do not sit at the same place on the evidence ladder. One has a completed Phase 3 randomised trial. One has only early-phase human pharmacology. One rests mainly on animal work. A 2026 review in Frontiers in Endocrinology stratifies the whole GH-IGF1 field 'from regulatory-grade randomised trial data to a complete absence of human studies'^[1]. This companion to our GH-axis primer sorts each candidate by that measure, so you can weight the claims for yourself.

An evidence ladder for GH-axis peptides

Four rungs are worth keeping separate. The top rung is a completed randomised controlled trial that measured a clinical outcome in the population the drug is used for. Below it is early-phase human work that measured hormone levels (growth hormone and IGF-1) but not outcomes like fat loss, lean mass or recovery. Below that is preclinical evidence in animals or cell models. The bottom rung is anecdote: forum reports and clinic testimonials with no controlled comparison. The Frontiers review makes the same point in clinical language, warning that self-administration protocols run at doses and durations the human studies never tested^[1]. Knowing which rung a claim comes from is most of the work.

Tesamorelin: a real Phase 3 trial, for one indication

Tesamorelin is the only peptide of the three with top-rung evidence. In a randomised, double-blind, placebo-controlled trial of 412 patients with HIV and abdominal fat accumulation, published in the New England Journal of Medicine in 2007, 26 weeks of daily 2 mg tesamorelin cut visceral adipose tissue by 15.2% while the placebo group gained 5.0%, and raised IGF-1 by 81%^[2]. That is a genuine outcome trial with a hard imaging endpoint, and it is why tesamorelin is approved in the United States as Egrifta SV for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy^[3].

The catch is scope. The trial population was people with HIV-associated lipodystrophy, not healthy adults chasing body composition or slower aging. No completed Phase 3 trial supports those off-label uses. The label itself flags the axis-level trade-off, telling prescribers to check glucose before starting and to monitor IGF-1 during treatment^[3]. So the honest reading is strong evidence, narrow indication. The full regulatory picture is on the tesamorelin regulation section.

CJC-1295: hormone levels, not outcomes

CJC-1295 sits one rung down. Its strongest human data is a 2006 randomised, placebo-controlled study in the Journal of Clinical Endocrinology and Metabolism, which gave subcutaneous doses to healthy adults aged 21 to 61 and tracked the hormonal response. A single injection raised mean growth hormone 2 to 10 times baseline for six days or more and IGF-1 by 1.5 to 3 times baseline for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days^[4]. The albumin-binding modification that produces that multi-day profile is what makes CJC-1295 pharmacologically interesting.

But read what the trial measured: blood levels of two hormones. It did not measure body composition, muscle strength, bone density or recovery, and it was not designed to. There is no completed and published Phase 2 or Phase 3 efficacy trial of CJC-1295 for any physique or performance outcome. Raised GH and IGF-1 on a lab report is a plausible mechanism, not a proven result, and treating the pharmacokinetic finding as if it were an outcome is the most common overreach in this literature. Country-by-country status sits on the CJC-1295 regulation section.

Ipamorelin: mostly animal and mechanistic

Ipamorelin is another rung down again. The foundational paper, published in the European Journal of Endocrinology in 1998, characterised it as the first selective growth-hormone secretagogue: in rats and swine it released growth hormone with potency comparable to GHRP-6 but, unlike the older GHRPs, did not meaningfully raise ACTH, cortisol or prolactin^[5]. That selectivity is the whole reason ipamorelin kept attracting attention.

What is missing is human outcome data. There is no published controlled efficacy trial establishing that ipamorelin improves body composition, recovery or any clinical endpoint in people. The evidence is animal work plus early human pharmacology, and the Frontiers review places compounds like it toward the thin end of its spectrum^[1]. Anyone weighting ipamorelin should treat the selectivity story as a mechanism worth studying, not as a demonstrated benefit. The ipamorelin regulation section covers where it stands legally.

The stack claims rest on mice

The popular protocol pairs CJC-1295 with ipamorelin on the argument that hitting two receptors amplifies growth-hormone release. A 2026 primer in the American Journal of Sports Medicine reviewed the injectable-peptide evidence for orthopaedic physicians and reported that the CJC-1295 plus ipamorelin combination improved maximum tetanic tension in murine models, while stating plainly that the finding is 'limited to animal studies' and that 'information regarding the indications, dosing, frequency, and duration of treatment remains unknown'^[6]. So the most-repeated combination claim currently lives on the animal rung. It may translate to humans, or it may not, and no trial has tested the question.

How to weight it

The short version: only tesamorelin has a completed human outcome trial, and only for HIV-associated lipodystrophy^[2]. CJC-1295 has human data that stops at hormone levels^[4]. Ipamorelin and the combination rest on animal and mechanistic work^[5][6]. None of that supports the healthy-adult, body-composition or anti-aging use these peptides are usually marketed for, because no trial has measured those outcomes in that population^[1].

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed here may be classified as prescription medicines or unlicensed research chemicals depending on your jurisdiction. Growth-hormone-axis stimulation carries real metabolic trade-offs, including effects on glucose and IGF-1 that a lab can track. If you are considering any of these compounds, talk to a qualified healthcare professional who can review your history and monitoring. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.